Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64042056 in preclinical Alzheimer's disease
ISRCTN78730935Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2024
- Modality
- Vaccines & Immunotherapeutics, Peptides
01
Overview
Phase 2, randomised trial in Alzheimer's disease (AD) comparing JNJ-64042056 with Placebo (2 arms). Primary endpoint: Change from baseline in PACC-5 total score. Started May 2024; status: recruiting.
02
Drugs
ACI-35
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ISRCTN78730935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN78730935.